4Mckelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators[J]. Circulation, 1999,100:1056-1064.
5Pitt B,Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with sever heart failure: Randomized Aldactone Evaluation Study Investigators[J]. N Engl J Med, 1999,341:709-717.
6Bauersachs J, Heek M, Fraccarollo D, et al. Addition of spironolactone to angiotensin- converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression[J]. J Am Coll Cardiol, 2002,39;351-358.
7Beggah AT, Escoubet B, Puttini S, et al. Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes[J].Proc Natl Acad Sci USA,2002,99(10):7160-7165.
二级参考文献1
1Bertram Pitt M.D.. “Escape” of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy[J] 1995,Cardiovascular Drugs and Therapy(1):145～149
